Literature DB >> 8852491

Calcium-free hemodialysis for the management of hypercalcemia.

W S Koo1, D S Jeon, S J Ahn, Y S Kim, Y S Yoon, B K Bang.   

Abstract

The drug therapies for hypercalcemia of malignancy have been known to be associated with either limited efficacy or cumulative toxicity in patients with advanced renal failure. To establish the guidelines for the use of dialysis and to determine its optimal prescription for hypercalcemia, calcium-free hemodialysis was performed in 6 hypercalcemic patients with renal failure not responding enough to forced saline diuresis. Calcium-free dialysate contained sodium 135, potassium 2.5, chloride 108, magnesium 0.75, bicarbonate 30 mmol/l. Mean hemodialysis time was 160 +/- 27 min and mean Kt/V urea was 0.75 +/- 0.2. Plasma calcium concentrations fell from a mean value of 2.92 +/- 0.21 mmol/l (range 2.55-3.25) to 2.58 +/- 0.16 mmol/l at 1 h of hemodialysis and to 2.16 +/- 0.33 mmol/l (range 1.63-2.53) following 2-3 h of hemodialysis. The ionized calcium (n = 4) decreased from 1.44 +/- 0.14 mmol/l to 0.99 +/- 0.2 mmol/l. No patient showed any hypocalcemic symptoms and signs during hemodialysis. The rate of decrease in plasma calcium did not appear to produce adverse effects in any of the patients. There was a significant positive correlation between the decrease in plasma calcium concentration and the Kt/V urea (y = 1.4x - 0.29, r = 0.92, p < 0.01). We conclude that calcium-free hemodialysis is indicated when the presence of severe renal failure prevents the administration of large volumes of intravenous fluids to hypercalcemic patients. The amount of dialysis (Kt/V urea) can be used to predict the decrease in plasma calcium concentration during calcium-free hemodialysis.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8852491     DOI: 10.1159/000188907

Source DB:  PubMed          Journal:  Nephron        ISSN: 1660-8151            Impact factor:   2.847


  7 in total

1.  Calcium-free hemodialysis for hypercalcemia of malignancy in a newborn.

Authors:  Madhura Pradhan; Mary B Leonard
Journal:  Pediatr Nephrol       Date:  2003-04-05       Impact factor: 3.714

2.  Fine-tuned continuous renal replacement therapy with calcium-free dialysate to manage severe hypercalcemia refractory to medical and intermittent hemodialysis.

Authors:  Marc Scheen; Grzegorz Nowak; Bienvenido Sanchez; Daniel Teta
Journal:  Eur J Med Res       Date:  2022-06-08       Impact factor: 4.981

3.  A fatal case of iatrogenic hypercalcemia after calcium channel blocker overdose.

Authors:  Michael T Sim; Frazier T Stevenson
Journal:  J Med Toxicol       Date:  2008-03

4.  [Tumor-induced hypercalcemia].

Authors:  O Hopfer; A Gawliczek; M G Kiehl
Journal:  Internist (Berl)       Date:  2013-09       Impact factor: 0.743

Review 5.  Clinical review: timing of renal replacement therapy.

Authors:  Michael Joannidis; Lui G Forni
Journal:  Crit Care       Date:  2011-06-10       Impact factor: 9.097

Review 6.  Hypercalcemia of Malignancy: An Update on Pathogenesis and Management.

Authors:  Aibek E Mirrakhimov
Journal:  N Am J Med Sci       Date:  2015-11

Review 7.  Hypercalcemia of malignancy and new treatment options.

Authors:  Hillel Sternlicht; Ilya G Glezerman
Journal:  Ther Clin Risk Manag       Date:  2015-12-04       Impact factor: 2.423

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.